AZD1236   Click here for help

GtoPdb Ligand ID: 7844

Synonyms: AZD 1236 | AZD-1236
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD1236 is a selective MMP-9 and MMP-12 inhibitor (IC50 4.5 and 6.1nM) from Astrazeneca that, since it failed biomarker endpoints for COPD is included in the AZ Open Innovation 2014 set for repurposing. Pending any published link the structure identification is tenatative but seems likely to be the structure crystalised in WO2007106022.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 126.08
Molecular weight 402.08
XLogP 1.93
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C1NC(=O)C(N1)(C)CS(=O)(=O)N1CCC(CC1)Oc1ccc(cn1)Cl
Isomeric SMILES O=C1NC(=O)[C@@](N1)(C)CS(=O)(=O)N1CCC(CC1)Oc1ccc(cn1)Cl
InChI InChI=1S/C15H19ClN4O5S/c1-15(13(21)18-14(22)19-15)9-26(23,24)20-6-4-11(5-7-20)25-12-3-2-10(16)8-17-12/h2-3,8,11H,4-7,9H2,1H3,(H2,18,19,21,22)/t15-/m1/s1
No information available.
Summary of Clinical Use Click here for help
A Phase 2a study evaluated the effects of AZD1236 on the biomarkers of inflammation and emphysematous lung tissue degradation in patients with moderate-to-severe COPD [2]. No clinical efficacy was demonstrated but evidence of an impact on desmosine suggests potential value in longer-term treatment of COPD.